Nadifloxacin
As of the edition of 20 October 2026, Nadifloxacin is a small molecule: marketed, first approved in 2001 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2001
- Kind
- Small molecule
- Brand name
- Nadixa
- First approved
- 9 October 2001 (ES)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Ferrer Internacional
- Registered trials
- 2, 0 stopped early
- Disease areas
- Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 0 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 2005 to now |